Global Erectile Dysfunction (ED) Drugs Market 2019-2023
SKU ID : TNV-14098806 | Publishing Date : 27-Mar-2019 | No. of pages : 121
Detailed TOC of Global Erectile Dysfunction (ED) Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Oral drugs - Market size and forecast 2018-2023
• Topical drugs - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• Eli Lilly and Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• VIVUS Inc.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for ED
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Oral drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Oral drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Sales of VIAGRA and CIALIS 2016-2018
Exhibit 23: Topical drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Topical drugs - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Bayer AG - Vendor overview
Exhibit 48: Bayer AG - Business segments
Exhibit 49: Bayer AG - Organizational developments
Exhibit 50: Bayer AG - Geographic focus
Exhibit 51: Bayer AG - Segment focus
Exhibit 52: Bayer AG - Key offerings
Exhibit 53: Eli Lilly and Company - Vendor overview
Exhibit 54: Eli Lilly and Company - Business segments
Exhibit 55: Eli Lilly and Company - Organizational developments
Exhibit 56: Eli Lilly and Company - Geographic focus
Exhibit 57: Eli Lilly and Company - Segment focus
Exhibit 58: Eli Lilly and Company - Key offerings
Exhibit 59: Pfizer Inc. - Vendor overview
Exhibit 60: Pfizer Inc. - Business segments
Exhibit 61: Pfizer Inc. - Organizational developments
Exhibit 62: Pfizer Inc. - Geographic focus
Exhibit 63: Pfizer Inc. - Segment focus
Exhibit 64: Pfizer Inc. - Key offerings
Exhibit 65: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 66: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 67: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 68: Teva Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 69: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 70: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 71: VIVUS Inc. - Vendor overview
Exhibit 72: VIVUS Inc. - Business segments
Exhibit 73: VIVUS Inc. - Organizational developments
Exhibit 74: VIVUS Inc. - Geographic focus
Exhibit 75: VIVUS Inc. - Key offerings
Exhibit 76: Validation techniques employed for market sizing
Keyplayers in Global Erectile Dysfunction (ED) Drugs Market 2019-2023
Bayer AGEli Lilly and Company
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
VIVUS Inc.